USUI JOICHI1, GLEZERMAN ILYA G3, CHANDRAN selleck screening library CHANDRA B4, SALVATORE STEVEN P2, FLOMBAUM CARLOS D3, SESHAN SURYA V2 1University of Tsukuba; 2Weill Cornell Medical College, Cornell University; 3Memorial Sloan-Kettering Cancer Center; 4St. Joseph’s Regional Medical Center Introduction: Cancer therapies have been supplemented by vascular endothelial growth factor(VEGF) inhibitors as anti-angiogenic agents in the recent years. The present work discloses the spectrum of pathological features in VEGF inhibitor-associated kidney disease. Methods: Pathological findings of kidney disease were retrospectively studied in 4 cancer patients treated

with VEGF inhibitors, bevacizumab (anti-VEGF-A), RXDX-106 cost with chemotherapeutic agents. Results: All patients

presented with acute kidney injury. All kidney biopsies showed endothelial injury of varying severity, including one with typical active features of thrombotic microangiopathy(TMA). Evidence of chronic endothelial injury and vascular sclerosis were also observed. Furthermore, acute tubular injury with focal necrosis was seen in all cases. Conclusion: A range of renal pathologic lesions secondary to endothelial injury are noted often accompanied by acute tubular damage following anti-VEGF therapy, the most severe being TMA. The role of other nephrotoxic chemotherapeutic agents in enhancing renal injury and other host factors with possible pathological variety should be considered. RAPUR RAM1, ADIRAJU KRISHNA PRASAD2, GUDITI SWARNALATHA2, GAURISHANKAR SWARNALATHA3, KALIGOTLA VENKATA DAKSHINAMURTY3 1Sri Venkateswara Insitute of Medical Sciences, Tirupati; 2Nizam’s Institute of Medical Sciences, Hyderabad; 3Apollo Hospitals, Hyderabad Introduction: Introduction: Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired chronic disorder characterized by a triad of clinical features- haemolytic anaemia, pancytopenia, and thrombosis. Not many

reports of renal involvement in PNH are available in literature. We present a case series of PNH with renal involvement. Methods: Materials and methods: We present the data of PNH patients Thalidomide attended to departments of General Medicine and Nephrology at a government run tertiary care institute in South India. The patients’ data was maintained on an out- patient case record. The diagnosis of PNH in these patients during initially phase, between 1998 and 2004 was based on sucrose lysis and Ham’s test. After 2004, the diagnosis was based on flow cytometry to detect CD59 (MIRL), a glycoprotein, and CD55 (DAF) in regulation of complement action. Results: The patient data was collected from 1998 to 2012. There were 26 patients of paroxysmal nocturnal haemoglobinuria in this period. The mean age was 37 years and the range was 16 to 68 years. There were 14 females. ARF was noted in ten patients.